# ALS Phase II Study of NX210c

> **NCT06365216** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Axoltis Pharma** · enrollment: 80 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** NX210c
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06365216
- **Lead sponsor:** Axoltis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-25
- **Primary completion:** 2026-02-01
- **Final completion:** 2026-09-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06365216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06365216, "ALS Phase II Study of NX210c". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06365216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*